BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...Co. Ltd. (Tokyo:4502; NYSE:TAK) acquired, and Syndax Pharmaceuticals Inc. (NASDAQ:SNDX). Henk Schuring joined neurodegenerative disease company Prilenia Therapeutics B.V....
BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

...disease progression by only a few months. Hayden has been serving as executive chairman of Prilenia Therapeutics B.V....
...consists of two tranches, with the second contingent on clinical progress, Hayden said. COMPANY PROFILE Prilenia Therapeutics B.V....
Items per page:
1 - 2 of 2
BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...Co. Ltd. (Tokyo:4502; NYSE:TAK) acquired, and Syndax Pharmaceuticals Inc. (NASDAQ:SNDX). Henk Schuring joined neurodegenerative disease company Prilenia Therapeutics B.V....
BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

...disease progression by only a few months. Hayden has been serving as executive chairman of Prilenia Therapeutics B.V....
...consists of two tranches, with the second contingent on clinical progress, Hayden said. COMPANY PROFILE Prilenia Therapeutics B.V....
Items per page:
1 - 2 of 2